Novel molecular diagnostic marker in the evaluation of cartilage destruction in patients with rheumatoid arthritis
المؤلفون المشاركون
Hasan, Ghadah
Muhammad, Ibtsam Faruq
Ibrahim, Usamah
المصدر
Journal of Current Medical Research and Practice
العدد
المجلد 1، العدد 3 (31 ديسمبر/كانون الأول 2016)، ص ص. 72-78، 7ص.
الناشر
تاريخ النشر
2016-12-31
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Aim The aim of this study was to evaluate the serum levels of cartilage oligomeric matrix protein (COMP) in rheumatoid patients in correlation with disease severity and cartilage destruction and to evaluate the therapeutic effectiveness of slow‑remitting agents such as leflunomid on this marker of cartilage destruction.
Patients and methods Fifty patients with rheumatoid arthritis (RA) diagnosed on the basis of the 2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria and 20 age‑matched and sex‑matched controls were enrolled in the study.
C‑reactive protein, erythrocyte sedimentation rate (ESR), rheumatoid factor, anti‑ cyclic citrullinated peptide, and COMP were determined.
Patients were classified into two groups according to Disease Activity Score‑28: group 1 (29 patients) included patients with severe activity with a score of greater than 5.1; and group 2 (21 patients) included patients with moderate activity with a score of greater than 3.2 and less than and equal to 5.1.
The studied patients were classified into two groups on the basis of the time of receiving leflunomid therapy (20 mg daily after initial therapy 100 mg daily for 3 days) for 3 months: group 3 received before treatment and group 4 received after treatment.
Results Serum COMP was significantly higher in patients with RA when compared with controls (P = 0.000).
The COMP levels were found to be positively correlated with Joint space narrowing score (JSN) (r = 0.832, P = 0.000) and erosion score (r = 0.863, P = 0.000) of radiography and negatively correlated with rheumatoid factor (r=−0.313, P = 0.027); however, COMP levels did not correlate with age (r = 0.231, P = 0.106), duration of disease (r = −0.060, P = 0.678), Disease Activity Score‑28 (r = −0.098, P = 0.498), C‑reactive protein (r = −0.242, P = 0.090), ESR first hour (r = −0.096, P = 0.509), ESR second hour (r = −0.101, P = 0.484), or anti‑cyclic citrullinated peptide (r = 0.041, P = 0.775).
Conclusion COMP could be a useful biomarker for the detection of early cartilage and bone destruction and in the follow‑up of disease severity and treatment in RA.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Hasan, Ghadah& Abu al-Nur, al-Badri& Ibrahim, Usamah& Muhammad, Ibtsam Faruq. 2016. Novel molecular diagnostic marker in the evaluation of cartilage destruction in patients with rheumatoid arthritis. Journal of Current Medical Research and Practice،Vol. 1, no. 3, pp.72-78.
https://search.emarefa.net/detail/BIM-760454
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Hasan, Ghadah…[et al.]. Novel molecular diagnostic marker in the evaluation of cartilage destruction in patients with rheumatoid arthritis. Journal of Current Medical Research and Practice Vol. 1, no. 3 (Dec. 2016), pp.72-78.
https://search.emarefa.net/detail/BIM-760454
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Hasan, Ghadah& Abu al-Nur, al-Badri& Ibrahim, Usamah& Muhammad, Ibtsam Faruq. Novel molecular diagnostic marker in the evaluation of cartilage destruction in patients with rheumatoid arthritis. Journal of Current Medical Research and Practice. 2016. Vol. 1, no. 3, pp.72-78.
https://search.emarefa.net/detail/BIM-760454
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 77-78
رقم السجل
BIM-760454
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر